|Bid||6,226.00 x N/A|
|Ask||6,230.00 x N/A|
|Day's Range||6,134.00 - 6,248.00|
|52 Week Range||4,905.16 - 6,604.00|
|Beta (5Y Monthly)||0.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2022|
|Forward Dividend & Yield||1.75 (2.83%)|
|Ex-Dividend Date||Apr 28, 2022|
|1y Target Est||7,201.25|
Subscribe to Yahoo Finance Plus to view Fair Value for RKT.L
If you want to know who really controls Reckitt Benckiser Group plc ( LON:RKT ), then you'll have to look at the makeup...
Reckitt Benckiser cannot seem to catch a break. The planned sale of its infant formula business, acquired from Mead Johnson in 2017, looks set to be ambushed by politics. A formula shortage in the US, set off by a shuttered Abbott Laboratories factory, has highlighted the sector’s oligopolistic nature.
After five years of talks with American regulators, British infant formula maker Kendal Nutricare finally began shipping to the US this month — but only after a national shortage forced Washington to approve emergency airlifts by foreign suppliers. The crisis was sparked in February when a safety scandal forced Abbott Laboratories to shutter a plant in Michigan that supplied 15 per cent of US formula. As shortages persist despite a ramp-up in production at other US factories and the temporary approval of foreign supplies, Abbott, a $180bn medical device and healthcare company, is facing a political firestorm.